RE/MAX Q1 Earnings Beat Expectations Despite Revenue Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 53 minutes ago
0mins
Should l Buy RMAX?
Source: seekingalpha
- Earnings Beat: RE/MAX reported a Q1 GAAP EPS of $0.16, exceeding expectations by $0.04, indicating resilience in profitability despite market challenges.
- Revenue Decline: The company posted revenues of $70.23 million, a 5.7% year-over-year decline, missing estimates, which reflects potential pressures from a sluggish real estate market.
- M&A Activity: RE/MAX is merging with The Real Brokerage, with an enterprise value of approximately $880 million, which could enhance the company's scale and market share.
- Positive Stock Reaction: Following reports of a potential sale of a tech real estate firm, RE/MAX shares surged 15%, demonstrating market optimism regarding the company's future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RMAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RMAX
Wall Street analysts forecast RMAX stock price to fall
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 10.630
Low
9.00
Averages
9.00
High
9.00
Current: 10.630
Low
9.00
Averages
9.00
High
9.00
About RMAX
RE/MAX Holdings, Inc. is a franchisor in the real estate industry, franchising real estate brokerages globally under the REMAX brand, and mortgage brokerages within the United States under the Motto Mortgage brand. Its segments include Real Estate, Mortgage, and Marketing Funds. Real Estate segment comprises the operations of the Company's owned and independent global franchising operations under the RE/MAX brand along with corporate-wide shared services expenses. The mortgage segment comprises the operations of the Company’s mortgage brokerage franchising operations under the Motto brand and mortgage loan processing services under the wemlo brand. The Motto franchise model offers United States real estate brokers, mortgage professionals and other investors access to the mortgage brokerage industry. Marketing Funds segment comprises the operations of its marketing campaigns designed to build and maintain brand awareness and the development and operation of agent marketing technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RE/MAX Reports Q1 Revenue Drop to $70.2 Million Amid Merger Plans
- Revenue Decline: RE/MAX Holdings reported first-quarter revenue of $70.2 million, down 5.7% from $74.5 million in Q1 2025, primarily due to a decrease in U.S. agent count and adjustments to standard fee models, which negatively impacted the company's overall financial performance.
- Adjusted EBITDA Decrease: The adjusted EBITDA for Q1 was $15.6 million, reflecting a 19.3% decline year-over-year, driven by lower revenue and increased transaction costs related to the merger, indicating financial pressure during the company's transition.
- Rising Operating Expenses: Total operating expenses rose to $78.1 million in Q1, a 13% increase from the previous year, primarily due to settlement charges and higher selling, operating, and administrative expenses, further squeezing the company's profit margins.
- Widening Net Loss: RE/MAX Holdings experienced a net loss of $9.7 million in Q1 2026, significantly up from a $2.0 million loss in Q1 2025, highlighting the severe impact on profitability amid market challenges and internal adjustments.
See More
Investigation Launched into RE/MAX Holdings' Merger Deal
- Board Investigation: Bleichmar Fonti & Auld LLP has initiated an investigation into RE/MAX Holdings, Inc.'s board and co-founder David Liniger, focusing on potential breaches of fiduciary duties related to the merger with The Real Brokerage Inc., which may impact shareholder interests.
- Merger Details: On April 27, 2026, RE/MAX announced its agreement to be acquired by The Real Brokerage, allowing shareholders to choose between $13.80 in cash per share or 5.15 shares of the post-merger entity, raising concerns about the fairness of the merger price.
- Price Fairness Issues: The investigation centers on whether the merger was executed at an unfairly low price and whether insiders at RE/MAX are receiving potentially unfair benefits that are not shared with public shareholders, which could harm shareholder rights.
- Legal Options: Current RE/MAX shareholders are encouraged to submit their information for legal support, with BFA offering representation on a contingency fee basis, emphasizing their commitment to protecting shareholder rights.
See More
RE/MAX Q1 Earnings Beat Expectations Despite Revenue Decline
- Earnings Beat: RE/MAX reported a Q1 GAAP EPS of $0.16, exceeding expectations by $0.04, indicating resilience in profitability despite market challenges.
- Revenue Decline: The company posted revenues of $70.23 million, a 5.7% year-over-year decline, missing estimates, which reflects potential pressures from a sluggish real estate market.
- M&A Activity: RE/MAX is merging with The Real Brokerage, with an enterprise value of approximately $880 million, which could enhance the company's scale and market share.
- Positive Stock Reaction: Following reports of a potential sale of a tech real estate firm, RE/MAX shares surged 15%, demonstrating market optimism regarding the company's future prospects.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Helix Energy Solutions Group, Inc. and Hornbeck Offshore Services, Inc., with Helix shareholders expected to own approximately 45% of the combined entity, potentially impacting shareholder rights and future earnings.
- Acquisition Review: Organon & Co. is being sold to Sun Pharmaceutical Industries Limited for $14.00 per share, and Halper Sadeh LLC may seek increased compensation and additional disclosures to ensure shareholder rights are protected.
- Equity Transaction: XOMA Royalty Corporation is being sold to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC representing shareholders to investigate the compliance of this transaction and ensure fair terms for shareholders.
- RE/MAX Deal: RE/MAX Holdings, Inc. is in a transaction with The Real Brokerage Inc., allowing shareholders to choose either 5.152 shares or $13.80 in cash per share, with Halper Sadeh LLC providing legal support to safeguard shareholder interests.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, RE/MAX Holdings, Inc., and Galera Therapeutics, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholders' financial interests.
- XOMA Transaction Details: XOMA Royalty Corporation is being sold to Ligand Pharmaceuticals Incorporated for $39.00 per share, a transaction that may limit the emergence of superior competing offers, thereby affecting shareholders' options.
- RE/MAX Shareholder Choices: Shareholders of RE/MAX Holdings, Inc. can choose to sell their shares for either 5.152 shares of the combined company or $13.80 in cash per share, with Halper Sadeh LLC encouraging shareholders to understand their rights and options to ensure fair treatment.
- Galera Merger Impact: The merger between Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc. is expected to result in Galera shareholders owning approximately 1.8% of the combined company, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures to protect shareholder interests.
See More
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
RE/MAX Reports Q1 Revenue Drop to $70.2 Million Amid Merger Plans
- Revenue Decline: RE/MAX Holdings reported first-quarter revenue of $70.2 million, down 5.7% from $74.5 million in Q1 2025, primarily due to a decrease in U.S. agent count and adjustments to standard fee models, which negatively impacted the company's overall financial performance.
- Adjusted EBITDA Decrease: The adjusted EBITDA for Q1 was $15.6 million, reflecting a 19.3% decline year-over-year, driven by lower revenue and increased transaction costs related to the merger, indicating financial pressure during the company's transition.
- Rising Operating Expenses: Total operating expenses rose to $78.1 million in Q1, a 13% increase from the previous year, primarily due to settlement charges and higher selling, operating, and administrative expenses, further squeezing the company's profit margins.
- Widening Net Loss: RE/MAX Holdings experienced a net loss of $9.7 million in Q1 2026, significantly up from a $2.0 million loss in Q1 2025, highlighting the severe impact on profitability amid market challenges and internal adjustments.
See More
Investigation Launched into RE/MAX Holdings' Merger Deal
- Board Investigation: Bleichmar Fonti & Auld LLP has initiated an investigation into RE/MAX Holdings, Inc.'s board and co-founder David Liniger, focusing on potential breaches of fiduciary duties related to the merger with The Real Brokerage Inc., which may impact shareholder interests.
- Merger Details: On April 27, 2026, RE/MAX announced its agreement to be acquired by The Real Brokerage, allowing shareholders to choose between $13.80 in cash per share or 5.15 shares of the post-merger entity, raising concerns about the fairness of the merger price.
- Price Fairness Issues: The investigation centers on whether the merger was executed at an unfairly low price and whether insiders at RE/MAX are receiving potentially unfair benefits that are not shared with public shareholders, which could harm shareholder rights.
- Legal Options: Current RE/MAX shareholders are encouraged to submit their information for legal support, with BFA offering representation on a contingency fee basis, emphasizing their commitment to protecting shareholder rights.
See More
RE/MAX Q1 Earnings Beat Expectations Despite Revenue Decline
- Earnings Beat: RE/MAX reported a Q1 GAAP EPS of $0.16, exceeding expectations by $0.04, indicating resilience in profitability despite market challenges.
- Revenue Decline: The company posted revenues of $70.23 million, a 5.7% year-over-year decline, missing estimates, which reflects potential pressures from a sluggish real estate market.
- M&A Activity: RE/MAX is merging with The Real Brokerage, with an enterprise value of approximately $880 million, which could enhance the company's scale and market share.
- Positive Stock Reaction: Following reports of a potential sale of a tech real estate firm, RE/MAX shares surged 15%, demonstrating market optimism regarding the company's future prospects.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Helix Energy Solutions Group, Inc. and Hornbeck Offshore Services, Inc., with Helix shareholders expected to own approximately 45% of the combined entity, potentially impacting shareholder rights and future earnings.
- Acquisition Review: Organon & Co. is being sold to Sun Pharmaceutical Industries Limited for $14.00 per share, and Halper Sadeh LLC may seek increased compensation and additional disclosures to ensure shareholder rights are protected.
- Equity Transaction: XOMA Royalty Corporation is being sold to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC representing shareholders to investigate the compliance of this transaction and ensure fair terms for shareholders.
- RE/MAX Deal: RE/MAX Holdings, Inc. is in a transaction with The Real Brokerage Inc., allowing shareholders to choose either 5.152 shares or $13.80 in cash per share, with Halper Sadeh LLC providing legal support to safeguard shareholder interests.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, RE/MAX Holdings, Inc., and Galera Therapeutics, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholders' financial interests.
- XOMA Transaction Details: XOMA Royalty Corporation is being sold to Ligand Pharmaceuticals Incorporated for $39.00 per share, a transaction that may limit the emergence of superior competing offers, thereby affecting shareholders' options.
- RE/MAX Shareholder Choices: Shareholders of RE/MAX Holdings, Inc. can choose to sell their shares for either 5.152 shares of the combined company or $13.80 in cash per share, with Halper Sadeh LLC encouraging shareholders to understand their rights and options to ensure fair treatment.
- Galera Merger Impact: The merger between Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc. is expected to result in Galera shareholders owning approximately 1.8% of the combined company, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures to protect shareholder interests.
See More
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
